These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2706626)

  • 1. Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II).
    Tsai CM; Gazdar AF; Venzon DJ; Steinberg SM; Dedrick RL; Mulshine JL; Kramer BS
    Cancer Res; 1989 May; 49(9):2390-7. PubMed ID: 2706626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II).
    Kern DH; Morgan CR; Hildebrand-Zanki SU
    Cancer Res; 1988 Jan; 48(1):117-21. PubMed ID: 3334986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination cytotoxic effects of cis-diamminedichloroplatinum(II) and 5-fluorouracil with and without leucovorin against human non-small cell lung cancer cell lines.
    Tsai CM; Hsiao SH; Frey CM; Chang KT; Perng RP; Gazdar AF; Kramer BS
    Cancer Res; 1993 Mar; 53(5):1079-84. PubMed ID: 8382553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
    Bible KC; Kaufmann SH
    Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology.
    Debes A; Rommel F; Breise M; Willers R; Göbel U; Wessalowski R
    Klin Padiatr; 2002; 214(4):223-9. PubMed ID: 12165906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of synergy between cisplatin and cytarabine against ovarian carcinoma in vitro.
    Howell SB; Gill S
    Cancer Treat Rep; 1986 Mar; 70(3):409-10. PubMed ID: 3955553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of etoposide and cisplatin in an in vitro tumor model.
    Durand RE; Goldie JH
    Cancer Treat Rep; 1987; 71(7-8):673-9. PubMed ID: 3607781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-alpha and interferon-gamma combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer cell lines.
    Hand A; Pelin K; Halme M; Ekman A; Mattson M; Vallas M; Mattson K; Linnainmaa K; Husgafvel-Pursiainen K
    Anticancer Drugs; 1993 Jun; 4(3):365-8. PubMed ID: 8395259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
    Borsellino N; Belldegrun A; Bonavida B
    Cancer Res; 1995 Oct; 55(20):4633-9. PubMed ID: 7553641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.
    Adjei AA; Budihardjo II; Rowinsky EK; Kottke TJ; Svingen PA; Buckwalter CA; Grochow LB; Donehower RC; Kaufmann SH
    Clin Cancer Res; 1997 May; 3(5):761-70. PubMed ID: 9815747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells.
    Horio Y; Hasegawa Y; Sekido Y; Takahashi M; Roth JA; Shimokata K
    Cancer Gene Ther; 2000 Apr; 7(4):537-44. PubMed ID: 10811471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents.
    Barret JM; Kruczynski A; Etiévant C; Hill BT
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):479-86. PubMed ID: 12107553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of carboplatin combination with etoposide against leukemia/lymphoma cell lines].
    Akutsu M; Suzuki K; Tsunoda S; Kano Y
    Gan To Kagaku Ryoho; 1996 Feb; 23(3):297-302. PubMed ID: 8712822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET; Kelley M; Rockwell S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
    Uslu R; Borsellino N; Frost P; Gárban H; Ng CP; Mizutani Y; Belldegrun A; Bonavida B
    Clin Cancer Res; 1997 Jun; 3(6):963-72. PubMed ID: 9815772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
    Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
    J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
    Chou TC; Motzer RJ; Tong Y; Bosl GJ
    J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.